THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring

Status:Active, not recruiting
Conditions:Atrial Fibrillation, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Age Range:18 - Any
Start Date:September 2013
End Date:December 2016

Use our guide to learn which trials are right for you!

This Study Will Investigate the Association Between a Set of Single Nucleotide Polymorphisms (SNPs) and Atrial Fibrillation in Patients at High Risk of Developing Atrial Fibrillation. The SNPs Investigated Will Have Been Previously Shown to be Associated With the Atrial Fibrillation.

Our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide
polymorphisms (SNPs) that are associated with atrial fibrillation at the Genome Wide
Association Study (GWAS) level is associated with the development of atrial fibrillation
among previously undiagnosed patients at high risk for atrial fibrillation. A current
example of these SNPs is shown in Table 1. As a secondary hypothesis, we will test the
association between atrial fibrillation diagnosed in this study with a subset of SNPs
reported to be associated with atrial fibrillation and with fine-mapping SNPs. We will also
test the association between atrial fibrillation of less than and greater than 30 seconds
and a panel of approximately 10 SNPs.

Inclusion Criteria:

- Symptoms of high clinical suspicion for atrial fibrillation prompting referral for
ambulatory cardiac rhythm monitoring for potential atrial fibrillation.


- At high risk for atrial fibrillation, defined as any one of the following: ischemic
stroke with no defined etiology (In prior 6 months) [3, 4, 6, 7], hypertension [33],
increased body mass index (BMI >30kg/m2) [33], heart failure [33], clinically
significant murmur [33], prolonged PR interval on resting ECG [33], chronic kidney
disease [34], hypertrophic cardiomyopathy [35], congenital heart disease [36],
chronic obstructive pulmonary disease [37, 38], sleep apnea [39-41], thyroid disease
[42, 43], family history of atrial fibrillation [44], diabetes [45] or excess alcohol
consumption (Male > 14 drinks/week, Female >7 drinks/week)[46].

- Age 40 years or older

- Capable of providing informed consent

- Capable of wearing a Zio Patch for up to 14 days

- Capable of providing a blood sample

Exclusion Criteria:

- Previously documented atrial fibrillation or atrial flutter.

- Prior cardiac surgery (coronary artery bypass grafting, valve replacement or repair,
pericardial stripping, etc) within the past 30 days.

- Hyperthyroidism.

- Have known skin allergies, conditions, or sensitivities (e.g. allergy to adhesives,
psoriasis) as the Zio Patch should not be used on patients with known skin allergies,
conditions, or sensitivities.

- Are receiving pacing therapy.

- Are anticipated to receive or require external cardiac defibrillation during the
monitoring period.

- Are anticipated to have exposure to high frequency surgical equipment during the
monitoring period.
We found this trial at
10666 N Torrey Pines Rd
La Jolla, California 92037
(858) 554-9100
Principal Investigator: Douglas Gibson, MD
Scripps Clinic Scripps Clinic in Torrey Pines has been providing exceptional medical care to people...
La Jolla, CA
Click here to add this to my saved trials